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Abstract
Background: Conserved non-coding regions (CNR) have been shown to harbor gene expression regulatory
elements. Genetic variations in these regions may potentially contribute to complex disease susceptibility.
Methods: We targeted CNRs of cardiovascular disease (CVD) candidate gene, Na(+)-Ca(2+) exchanger (NCX1) with
polymorphism screening among CVD patients (n = 46) using DHPLC technology. The flanking region (348 bp) of
the 14 bp indel in intron 2 was further genotyped by DGGE assay in two Eastern-European CVD samples: essential
hypertension (HYPEST; 470 cases, 652 controls) and coronary artery disease, CAD (CADCZ; 257 cases, controls 413).
Genotype-phenotype associations were tested by regression analysis implemented in PLINK. Alignments of primate
sequences were performed by ClustalW2.
Results: Nine of the identified NCX1 variants were either singletons or targeted by commercial platforms. The 14
bp intronic indel (rs11274804) was represented with substantial frequency in HYPEST (6.82%) and CADCZ (14.58%).
Genotyping in Eastern-Europeans (n = 1792) revealed hypervariable nature of this locus, represented by seven
alternative alleles. The alignments of human-chimpanzee-macaque sequences showed that the major human
variant (allele frequency 90.45%) was actually a human-specific deletion compared to other primates. In humans,
this deletion was surrounded by other short (5-43 bp) deletion variants and a duplication (40 bp) polymorphism
possessing overlapping breakpoints. This indicates a potential indel hotspot, triggered by the initial deletion in
human lineage. An association was detected between the carrier status of 14 bp indel ancestral allele and CAD (P
= 0.0016, OR = 2.02; Bonferroni significance level alpha = 0.0045), but not with hypertension. The risk for the CAD
development was even higher among the patients additionally diagnosed with metabolic syndrome (P = 0.0014,
OR = 2.34). Consistent with the effect on metabolic processes, suggestive evidence for the association with heart
rate, serum triglyceride and LDL levels was detected (P = 0.04).
Conclusions: Compared to SNPs targeted by large number of locus-specific and genome-wide assays, considerably
less attention has been paid to short indel variants in the human genome. The data of genome dynamics,
mutation rate and population genetics of short indels, as well as their impact on gene expressional profile and
human disease susceptibility is limited. The characterization of NCX1 intronic hypervariable non-coding region
enriched in human-specific indel variants contributes to this gap of knowledge.
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Cardiovascular disease (CVD) is a complex disorder
affecting heart and blood vessels, which develops from
the interaction between life style patterns and genetic
susceptibility to the disease. Western societies face high
and increasing rates of CVD (such as coronary artery
disease, hypertension, arteriosclerosis, heart failure and
arrhytmia etc.), which is considered a number one cause
of premature death and disability. Although CVD has
been shown to have significant heritability, pinpointing
of the genes and variants associated with the elevated
risk to the disease has been challenging [1,2]. The focus
has slowly switched from DNA variants located in genic
regions causing direct changes in the encoded protein to
the regulatory variants affecting gene expression. Non-
coding variants potentially contributing to the suscept-
ibility to complex diseases are localized in promoters
and enhancers, introns or 5’-a n d3’-UTRs, and may
affect binding of the gene expression regulators, such as
transcription and splicing factors or miRNAs. Compara-
tive genetics studies have noted several essential gene
regulatory elements that are conserved among species
[3,4]. Thus, targeting evolutionarily conserved non-cod-
ing regions (CNR) in candidate genes for CVD may pin-
point regulatory elements directing the gene expression
profile. Genetic variation in these regions may contri-
bute to the susceptibility to CVD. Based on these
hypotheses we aimed to target human CVD candidate
gene Na(+)-Ca(2+) exchanger (NCX1; SLC8A1) with
polymorphism screening in CNRs and to test associa-
tions of identified variants with CVD and related meta-
bolic traits in two Eastern-European populations.
Na
+/Ca
2+ exchange participates in the regulation of
vascular function and thus, disturbances in this process
contribute to the development of CVD. Na
+/Ca
+2
exchanger (NCX1) is a bidirectional calcium transporter,
responsible for calcium homeostasis in cardiac myocytes
and in other cell types by catalyzing the exchange of
one Ca
2+ ion for three Na
+ ions across plasma mem-
brane [5]. Altered Na
+/Ca
2+ exchange activity has been
observed in arrhythmias, heart failure [6], and salt-sensi-
tive essential hypertension [7,8]. Ncx1
-/- mice showed
complete lack of Na
+/Ca
2+ exchange activity in heart
leading to the defects in heart development and embryo-
nic lethality [9].
NCX1 gene (498 908 bp) is located in chromosome
2p22.1 and consists of 12 alternatively spliced exons[10].
Alternative splicing of NCX1 produces several tissue-
specific isoforms [11] differing in their regulatory prop-
erties [12,13]. NCX1 alternative isoforms respond differ-
ently to potential therapeutic agents such as
polyunsaturated fatty acids [14] and specific NCX1 inhi-
bitors [9]. Currently, genetic studies targeting the
association of NCX1 polymorphisms with CVD are lim-
ited. Resequencing of the entire coding and promoter
regions in Japanese population identified 15 polymorph-
isms, two of these variants located >23 kb upstream of
the mRNA transcription start site were associated with
hypertension [8].
We have conducted a polymorphism screening in
NCX1 non-coding regions. The most potential genetic
variant to affect gene function, a 14 bp indel, localized
in an intronic hypervariable region was characterized in
detail in cardiovascular and metabolic traits in two Eur-
opean populations.
Methods
In silico analysis of conserved non-coding regions (CNR)
of NCX1
We screened NCX1 (also known as SLC8A1)l o c u sf o r
t h ep r e s e n c eo fC o n s e r v e dN o n - c o d i n gR e g i o n s( C N R s )
using the web-based VISTA software [15] with the pro-
posed default parameters (cutoff criteria: 100 bp sliding
window; sequence identity 70%; comparison with rat
and mouse). The analyzed NCX1 locus (in total 420,181
bp) spanned from 10 kb downstream to 10 kb upstream
of the gene [2p22.1; coordinates 40 241 046-40 661 226
according to NCBI Build 35, hg17; GenBank:6546]. All
VISTA regions that had any overlap with annotated
genes track at UCSC Genome Browser [16] were
excluded as potential coding regions. For polymorphism
discovery we selected 29 non-coding regions based on
the following criteria: the (i) length 50-300 bp; (ii) loca-
tion >200 bp from the nearest exons, and (iii) sequence
identity >70% between human and both rodents (See
additional file 1).
DHPLC screening of novel polymorphisms in NCX1 non-
coding regions
The selected NCX1 conserved non-coding segments
were targeted to polymorphism screening by Denaturing
High-Performance Liquid Chromatography method
(DHPLC; Wave Technologies Inc. USA). During the
design and experimental screening process of DHPLC
products the recommendations of the manufacturer
were followed. Details of DHPLC assay and running
conditions with appropriate PCR primers and fragment
characteristics are given in additional file 2. Among the
total 29 CNR-s selected, 16 intronic regions entered the
DHPLC screening (See additional file 1) phase. 13
regions were excluded before the laboratory experiments
due to failure in DHPLC primer design, inappropriate
length of the PCR and CNR fragment (too long >700 bp
or short <50 bp), or more than two different Tm melt-
ing points for the region of interest. The average length
of the screened CNR segments was 163 bp (SD: 64 bp,
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87 bp, range 170-489 bp). Polymorphism screening was
performed with 15 different DNA pools, each consisting
of DNAs of three patients with cardiovascular disease
originating from two Eastern European sample sets (n =
22 from HYPEST and n = 24 from CADCZ study;
detailed description is given below). Individual DNAs in
the pools exhibiting evidence for the presence of a poly-
morphism were sequenced at least twice on both for-
ward and reverse orientations.
DGGE genotyping assay
Genotyping of the identified 14 bp indel (rs11274804,
NCBI dbSNP database) in NCX1 intron 2 was per-
formed by standard Denaturing Gradient Gel Electro-
phoresis (DGGE) (Ingeny, Goes, Netherlands). The
manufacturer’s recommendations were followed in the
design of the DGGE assay and in choosing the condi-
tions for the experimental setup. Detailed information of
the assay is given in additional file 2. To initially validate
the reliability of the DGGE assay, all DNA samples with
alternative genotypes previously detected by DHPLC
were re-genotyped at the DGGE platform. To further
assure DGGE gel typing system’s quality in each assay,
double positive (product containing 14 bp indel) and
negative controls were used. All ambiguous genotypes in
DGGE analysis were re-genotyped twice and/or
sequenced on both DNA strands by an ABI 377 Prism
automated DNA sequencer using ReproGel 377 gels
(Amersham Biosciences Inc., USA). The sequences of all
novel variants were verified by resequencing twice on
both forward and reverse orientation.
Subjects for association studies with cardiovascular
disease
Two Eastern-European sample collection, HYPEST and
CADCZ were used to conduct association analysis of
rs11274804 with cardiovascular traits and serum bio-
markers (Table 1). The HYPEST study has been
approved by the Ethics Committee on Human Research
of University of Tartu (no. 122/13, 22.12.2003; 137/20,
25.04.2005). CADCZ study was approved by the Ethics
Committee of Charles University–1st Faculty of Medi-
cine (December 1996) and is published elsewhere [17].
The studies were carried out in compliance with the
Helsinki Declaration and all the participants have given
their written informed consent. These sample collections
have been recruited to target the genetic-epidemiological
component of cardiovascular disease in Estonian and
Czech populations, respectively. HYPEST subjects were
recruited across Estonia during 2004-2007 (1823 indivi-
duals, age range 18-85 years) with the aim to evaluate
risk factors for essential hypertension and related cardi-
ovascular disease. Details of the recruitment are given in
additional file 2. CADCZ subjects (n = 893; n = 296 cor-
onary artery disease patients, n = 597 controls) were
recruited by the Cardiology Department of the 2
nd
Clinic of Internal Medicine, Faculty Hospital Královské
Vinohrady in Prague Czech Republic and Czech heath
clinics in years 1998-2000 [17]. In order to exclude obe-
sity and age-related risks, the current study included
individuals with BMI <35 kg/m
2 and age <65 years.
From HYPEST individuals 470 hypertensive patients
and 652 normotensive controls, and from CADCZ sam-
ples 257 CAD patients and 413 controls, were analyzed.
The control group for both studies consisted of matched
healthy individuals with no personal history of CAD,
essential hypertension, MI, peripheral arterial disease, or
s t r o k e .A sn op o p u l a t i o nd i f ferentiation was detected
among HYPEST and CADCZ study subjects previously
[18], the controls of the two studies were pooled in
order to address the association of rs11274804 with car-
diovascular traits in general Eastern-European
population.
Cardiovascular phenotype
For all subjects in the HYPEST and CADCZ studies
resting blood pressure (BP) and heart rate were mea-
sured by trained clinicians during recruitment. In both
studies BP measurements per subject were obtained
after a rest in a sitting position using a standard mer-
cury column sphygmomanometer and size-adjusted
cuffs. All HYPEST individuals possessed a documented
history of multiple SBP and DBP readings (on average
4.31 readings per individual, range 2-29) during mean
3.17 years (range 1-17 years). To compensate for the
variability in heaviness of data per study subjects, we
used for the analysis the median across the longitudinal
BP readings as well as the median of the subject’sa g e
during the readings. Definition of essential hypertension
among HYPEST subjects is given in additional file 2.
For CADCZ subjects three blood pressure measure-
ments were documented and the median value was
recorded.
Coronary artery disease (CAD) in CADCZ study was
diagnosed according to WHO criteria, and one or more
large stenosis of a major coronary vessel was confirmed
by coronarography in all patients details of which have
been published elsewhere [17]. Carotid wall intima
media thickness (IMT) and the presence of carotid pla-
que, recorded in the CADCZ subjects were determined
by ultrasonography using linear exploring coil 7,5 MHz
on the distant interior wall about 1-2 cm distally from
the bifurcation. The measurement was performed on
the right and the left carotid 5-10 times on each side.
Diagnosis of metabolic syndrome was defined based on
the criteria appointed by International Diabetes Federa-
tion [19].
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Altered serum lipid profile is considered as a cardiovas-
cular risk factor - a condition that is associated with an
increased risk of developing CVD affecting the heart
and blood vasculature. In the current study, lipid mea-
surements (total-cholesterol, HDL-cholestrerol, LDL-
cholesterol and triglycerides, TG) were determined from
fasting venous blood samples in the HYPEST and
CADCZ subjects. For HYPEST total-cholesterol, HDL-
cholesterol, LDL-cholesterol, and triglycerides in the
serum were measured by standardized assays (Cobas
Integra 800® analytical platform, Roche Diagnostics, Inc.,
USA) at the United Laboratories, Tartu University Hos-
pital [20] or at the Diagnostics Division Laboratory, the
North Estonia Medical Centre [21]. For CADCZ, serum
lipids were measured by standard techniques in Institute
of Clinical Chemistry of Vinohrady Faculty Hospital.
Statistical analysis
For all identified polymorphisms, the deviation from
Hardy-Weinberg equilibrium and differences in allele
frequencies between populations were tested using an
exact test implemented in Genepop web Version 3.4
[22]. Four rare population-specific polymorphisms
showed differences in allele frequencies between the stu-
died individuals from HYPEST (n = 22) and CADCZ (n
= 24) (Fisher’s exact test, p < 0.05; data not shown).
There was no significant difference between the
HYPEST (n = 1122) and CADCZ (n = 670) study
groups (Fisher’s exact test, p > 0.05; data not shown) for
the distribution of the 14 bp indel polymorphism.
The significance of the associations between the NCX1
14 bp indel and cardiovascular traits was tested, and
odds ratios/effect sizes andc o n f i d e n c ei n t e r v a l sw e r e
obtained using linear (quantitative traits) and logistic
(case-control analysis) regression analyses implemented
in the PLINK software [23]. In all study stages the asso-
ciation analyses were performed under additive and
dominant genetic models. Additive genetic models
assume a trend per copy of the minor allele to contri-
bute to the trait or disease susceptibility on genotype
categories, whereas dominant genetic models assume
that heterozygotes have the same increased risk as
minor homozygous genotypes. Recessive genetic model
was not applied, as it requires a large sample size to
reach a reasonable statistical power. Meta-analysis was
performed using inverse variance method with fixed
effect model of both sample sets. Association tests were
performed with age, sex and BMI as co-variates. P-
values <0.05 were considered statistically significant.
Two additional corrections were used in the quantitative
parameter analysis: in the serum lipid biomarker analy-
sis, a correction according to Jun Wu was implemented
to all of the individuals obtaining lipid-lowering medica-
tions [24], and in the blood pressure (SBP and DBP)
association test, a correction described by Martin Tobin
was used for all subjects receiving antihypertensive
treatment [25]. For the multiple comparisons (11 traits
Table 1 Phenotypic characteristics of analyzed individuals
HYPEST CADCZ Healthy Eastern
Variable Cases Controls Cases Controls European individuals
1
No. of individuals 470 652 257 413 1065
Parameters (mean ± SD):
Age (years)
2 43.9 (13.0) 39.0 (4.9) 51.2 (8.1) 49.5 (7.4) 43.7 (9.7)
Body Mass Index (BMI) (kg/m
2) 28.7 (3.7) 24.4 (3.3) 27.9 (3.3) 25.3 (3.1) 24.7 (3.1)
Systolic blood pressure (SBP) (mmHg) 143.2 (17.6) 130.0 (22.7) 136.6 (19.2) 125.2 (14.0) 128.5 (12.2)
Diastolic blood pressure (DBP) (mmHg) 87.4 (10.6) 81.0 (14.6) 85.1 (11.3) 80.3 (9.3) 80.0 (8.2)
Total cholesterol (mmol/liter) 5.6 (1.1) 5.0 (1.4) 5.4 (1.0) 5.6 (1.0) 5.4 (1.1)
High-density lipoprotein (HDL) (mmol/liter) 1.5 (0.4) 1.7 (0.5) 1.2 (0.3) 1.5 (0.4) 1.5 (0.4)
Low-density lipoprotein (LDL) (mmol/liter) 3.8 (1.0) 3.3 (1.1) 3.2 (0.8) 3.4 (0.9) 3.3 (0.9)
Triacylglycerols (mmol/liter) 1.8 (1.6) 0.8 (0.3) 2.1 (1.3) 1.5 (1.1) 1.2 (1.1)
Intima media thickness (IMT) NA NA 0.7 (0.2) 0.6 (0.2) NA
Heart Rate (HR) (bpm) NA 71.0 (26.4) 76.0 (5.6) 74.8 (5.5) 74.0 (8.6)
Medication:
% of antihypertensive treatment 75.3% 0% 54.5% 0% 0%
% of antilipidemic treatment 20.2% 0% 58.4% 0% 0%
1Pooled HYPEST and CADCZ control subjects, who had no personal history of cardiovascular disease, including essential hypertension, myocardial infarction,
coronary artery disease, stroke, and had never been prescribed antihypertensive or other cardiovascular medications. Previously, no population differentiation
was detected between HYPEST and CADCZ study subjects[18]
2Cases: age at the onset of the essential hypertension (HYPEST) or coronary artery disease (CADCZ); Controls: age at the recruitment
mmHg - millimeters of mercury; bpm - beats per minute; NA - not available
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0.05/11 = 0.0045).
Multiple sequence alignment of the human, common
chimpanzee and rhesus macaque DNA sequences of the
orthologous regions adjacent to 14 bp indel within
NCX1 intron 2 was performed with web-based analysis
tool ClustalW2 [26]. LD structure (based on the Hap-
Map variation data) for the analyzed NCX1 genomic
region was performed with the Haploview package [27]
(See in additional file 3).
Results
DHPLC screening of polymorphisms in NCX1 non-coding
regions
We analyzed human cardiovascular candidate gene,
NCX1 (Na(+)-Ca(2+) exchanger, 2p22.1), for the con-
served non-coding regions using VISTA genome brow-
ser [15] with default parameters. In total, we identified
365 conserved non-coding regions between human and
m o u s ea n dr a t( M a y2 0 0 4 ,N C B IB u i l d3 3 ) .T h e s ec o n -
served non-coding regions (CNR) covered 15.1% of the
analyzed genomic region (gene ± 10 kb). Based on the
length (50-300 bp), location (>200 bp from the nearest
exon) and sequence conservation (>70% between human
and both rodents), 29 regions were selected for further
polymorphism screening among 46 East-European cardi-
ovascular disease patients (HYPEST n = 22; CADCZ n =
24). Due to the limitations of the technology and/or
complex structure of the DNA sequence, 13 of the
selected NCX1 regions did not qualify for the DHPLC
screening. The remaining 16 regions were subjected to
polymorphism discovery among cardiovascular pheno-
type patients. Detailed descriptions of the selected
r e g i o n sa sw e l la si n c l u s i o n / e x c l u s i o nc r i t e r i af o rt h e
analysis are given in additional file 1. In total, ten
genetic variants (including three novel variants) were
identified within the 16 analyzed regions (Table 2).
Most of the variations were located within the second
intron of the gene (first intron relative to ATG initiation
codon), including six SNPs, and one 14 bp indel
(rs11274804, NCBI dbSNP database). Two SNPs were
detected in the NCX1 intron 10 and one SNP in intron
4. Among the screened HYPEST samples (n = 22) three
common (minor allele frequency, MAF>10%) and four
rare (MAF<10%) variants were identified. Five poly-
morphisms detected in the studied CADCZ patients (n
= 24) were uncommon (MAF<10%) and four were com-
mon (MAF>10%). Four variants were specific to one of
the studied sample sets (either HYPEST or CADCZ).
Characterization of the intronic hypervariable region
Nine of the identified variants in screened NCX1 non-
coding regions were either singletons or targeted already
by commercial platforms and thus included in large
number of studies (Table 2). The current study focused
on the 14 bp indel (rs11274804), which was represented
with substantial frequency (6.82% in HYPEST; 14.58% in
CADCZ) in both study populations. In addition, the
location of rs11274804 indel variant in the second
intron of NCX1 ( t h ef i r s ti n t r o ni nt h ec o d i n gr e g i o n )
raised the hypothesis about its potential effect on the
gene transcription as several gene expression regulatory
Table 2 Polymorphisms detected by DHPLC in screened human NCX1 non-coding regions
Analyzed regions Detected variants
1
Contig positions in Chr.
2
2
Length (bp) Location Alleles
3 HYPEST
(hom/het)
4
CADCZ
(hom/het)
4
Validation/
rs-number
2
Targeted by genotyping
platform
5
40349616 293 intron 2 A/g ND 1/4 novel NA
40335702-40335701 348 intron 2 14 bp indel
6 0/3 0/7 rs11274804
6 NA
40335650 348 intron 2 C/g 0/1 0/1 novel NA
40407194 387 intron 2 C/g 0/1 1/3 rs72943138 Illumina
40277948 370 intron 2 T/c 3/6 0/2 rs449383 Affymetrix GeneChip
40475254 469 intron 2 A/t 3/9 0/1 rs2192773 Illumina
40301091 292 intron 2 a/G ND 1/1 rs2540904 Illumina
40246617 282 intron 4 T/c ND 0/1 novel NA
40514809 489 intron 10 A/g 3/9 0/5 rs4952414 Illumina
40514961 489 intron 10 c/T 0/1 ND rs17026003 Affymetrix GeneChip
1Polymorphism screening was performed using HYPEST (n = 22) and CADCZ (n = 24) cases. Detailed description of all targeted genomic regions and detected
variants is given in additional file 1.
2Contig positions and rs-numbers of the validated SNPs are given according to the Simple Nucleotide Polymorphisms database (dbSNP build 129; Human
Genome March 2006).
3Major and minor alleles are indicated with capital and lower case letters, respectively.
4Number of number of homozygotes/heterozygotes (hom/het) of each identified polymorphism among the screened individuals
5Commercial genotyping platforms, which include the described variants (according to NCBI database)
6the 14 bp indel: CATTCCCTCTCCAT/-
ND - not detected; NA - not available
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[28-30]. Thus, this polymorphism as well as its flanking
region was selected for further characterization.
The region flanking the 14 bp indel (348 bp) in NCX1
intron 2 was targeted for the larger-scale genotyping
using Denaturing Gradient Gel Electrophoresis (DGGE).
Our study samples, HYPEST (n = 1122) and CADCZ (n
= 670), displayed nine different genotype variants of this
intronic segment (representing seven novel alternative
alleles), detected by DGGE and confirmed by sequen-
cing (Figure 1). The analyzed region appeared to be
highly polymorphic in both sample collections. In addi-
tion to 14 bp indel, a SNP (C/G), a duplication of 40 bp
segment, and four alternative deletions (10 bp, 43 bp
and 5 bp) were localized within the 348 bp region (Fig-
ure 1, Table 3). The breakpoints of several detected var-
iants co-localized with the 14 bp indel (Figure 2b). The
allele frequencies of the detected variants in the full
genotyped sample (n = 1792) varied from singletons (10
bp deletion; 40 bp duplication) to common polymorph-
isms with allele frequencies up to 8.51% (14 bp indel).
The 43 bp deletion was enriched in HYPEST samples
(20 subjects in HYPEST versus 1 in CADCZ). One
HYPEST subject appeared to be a compound heterozy-
g o t ef o r1 4b pi n d e l / 4 3b pd e l etion. In total, 18.21% of
the genotyped HYPEST subjects and 20.49% of CADCZ
subjects were carrying alternative variants of the studied
NCX1 intron 2 segment (Table 3). Active genome
dynamics of the analyzed region is supported by its
location between two LD-blocks within the NCX1 gene
(See in additional file 3).
Identified 14 bp indel originates from a human-specific
deletion compared to ancestral primate sequence
In order to determine the ancestral primate variant of
the studied 348 bp region, thec o n s e n s u ss e q u e n c e so f
human, common chimpanzee and rhesus macaque were
aligned. In contrast to the expectations, multiple
sequence alignment (ClustalW2) revealed that the
ancestral primate variant is actually the minor human
allele carrying the 14 bp sequence motif. The major
human variant (among East-European subjects) has
evolved through a 14 bp human-specific deletion when
compared to sister-species chimpanzee and rhesus
macaque (Figure 2b).
Other identified short insertion-deletion variants
within the studied region have occurred in human line-
age on the chromosomal variant carrying the human-
specific 14 bp deletion (Figure 2b).
Association of the 14 bp indel with cardiovascular traits
Association of NCX1 intronic 14 bp indel (rs11274804)
with cardiovascular disease was studied in two Eastern
European sample sets: essential hypertension (HYPEST,
Estonia; n = 1122; cases n = 470/controls = 652) and
coronary artery disease, CAD (CADCZ, Czech; n = 670;
cases n = 257/controls = 413). Associations were
assessed using logistic regression under additive and
dominant effect models (age, sex, and BMI as covariates;
Table 4). NCX1 intronic 14 bp indel region revealed
strong association with the diagnosis of CAD (P =
0.0016, OR = 2.02; P = 0.0018, OR = 2.07; additive and
dominant models, respectively). As there are various
clinical conditions that comprise CAD, additional case-
control analysis was performed using patients diagnosed
with CAD as well as metabolic syndrome (n = 88).
Despite a three fold reduction in sample size compared
to the full CADCZ patient group, the analysis of CAD
patients with metabolic syndrome revealed highly signif-
icant association with increased effect size (P = 0.0014,
OR = 2.34; P = 0.0016, OR = 2.41; additive and domi-
nant models, respectively). These associations remained
Table 3 Distribution of insertion/deletion variants identified in the NCX1 intron 2 hypervariable region
HYPEST CADCZ
Cases Controls Cases Controls All
Number of studied individuals 470 652 257 413 1792
Detected genotypes
1 (n, %):
WT homozygote 379 (80.6%) 513 (78.7%) 192 (74.7%) 356 (86.2%) 1440
14 bp indel heterozygote 68 (14.5%) 117 (18.9%) 55 (21.4%) 53 (12.8%) 293
14 bp indel/C = >G compound heterozygote 8 (1.7%) 8 (1.2%) 5 (1.9%) 3 (0.7%) 24
14 bp indel homozygote 3 (0.6%) 1 2 (0.8%) 1 7
43 bp del heterozygote 10 (2.1%) 10 (1.5%) 1 0 21
40 bp duplication 10001
14 bp indel/43 bp del compound heterozygote 01001
5 bp del heterozygote 1 2 (0.3%) 1 0 4
10 bp del heterozygote 00101
1Exact sequences of detected alleles are given in Figure 2.
n = number of carriers of the genotype; indel - insertion/deletion; del - deletion
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roni significance level a = 0.05/11 = 0.0045).
NCX1 intronic 14 bp indel was not associated with the
diagnosis of essential hypertension in HYPEST sample
collection (P > 0.1).
Association of the 14 bp indel with quantitative
cardiovascular parameters
Associations of the 14 bp indel with quantitative cardio-
vascular parameters [systolic (SBP) and diastolic (DBP)
blood pressure, heart rate, Intima-Media Thickness
(IMT)], and serum lipid biomarkers [total cholesterol,
HDL, LDL, triglycerides (TG)] were evaluated by linear
regression under additive and dominant models (Table
5, Table 6). A marginal negative correlation was
detected with heart rate (P = 0.04, beta = -1.6; additive
model) and LDL (P =0 . 0 4 ,b e t a=- 0 . 2 6 ;d o m i n a n t
model) among healthy Eastern-European subjects (Table
5, Table 6). Association of the 14 bp indel with serum
triglyceride levels reached marginal significance in the
CADCZ sample (P = 0.04, beta = 0.25; both models)
and a non-significant trend for association in the joint
meta-analysis with HYPEST data (P = 0.08, beta = 0.18;
P = 0.07, beta = 0.19; additive and dominant models,
respectively). No significant association was detected
with other studied cardiovascular and serum lipid para-
meters in separate sample sets and in meta-analysis.
Discussion
We subjected the human NCX1 (Na
+/Ca
2+exchanger)
gene to polymorphism screening in conserved non-cod-
ing regions with the aim to identify novel potential reg-
ulatory variants, which may contribute to the
development of cardiovascular disease (CVD). So far,
fine-scale polymorphism discovery in the coding, and
promoter regions of the NCX1 gene have been carried
out only among Japanese individuals, where twopromo-
ter SNPs were shown to be associated with essential
hypertension [8] as one of the major risk factor for sev-
eral CVDs (i.e. CAD). We conducted the polymorphism
discovery in NCX1 non-coding conserved regions using
CVD patients from two Eastern-European sample col-
lections (HYPEST, essential hypertension; CADCZ, cor-
onary artery disease). Among the ten identified variants,
the genomic context of the 14 bp indel located in NCX1
gene intron 2 and its association with CVD was studied
in detail. First introns have previously been indicated to
contain essential regulatory elements and therefore, may
contribute to the transcriptional regulation processes
[31] and splicing. For example, in human CFTR gene a
regulatory intronic DNase I hypertensive site (DHS) was
shown to be required for the normal expression levels
in the intestinal epithelium in vivo [28]. The expression
profiles of human angiotensin II type 2 receptor AGTR2
and erythroid-specific GATA-1 are affected by regulatory
Figure 1 Detection of alternative genotype variants of human NCX1 intron 2 studied region (348 bp) by Denaturing Gradient Gel
Eelectorphoresis (DGGE). DGGE was performed using 9% polyacrylamide gel in 0.5 × TAE buffer containing 30-85% denaturing gradient of
ureumformamide. Electrophoresis conditions were 58°C, 12 h and 140 V.
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binding sites [29,30].
Genotyping of the 14 bp indel locus revealed the
hypervariable nature of the studied genomic segment
within NCX1 intron 2. Among the screened Eastern-
Europeans (n = 1792) the analyzed 348 bp region was
represented by seven different alleles (Figure 1, Figure
2). The alignments of human-chimpanzee-macaque
sequences revealed that the major human variant (allele
frequency 90.45%) was actually a human-specific dele-
tion compared to other primates. The most common
alternative variant, the 14 bp indel, appeared to have the
ancestral status among primates. Both, chimpanzee and
rhesus macaque possess this common 14 bp sequence
tract in their NCX1 intron 2 (Figure 2b). Either natural
selection or genetic drift may have contributed to the
enrichment of the novel 14 bp deletion variant among
humans. The data suggests that the novel deletion var-
iant may carry a selective advantage among humans as
it was found to be associated with decreased risk for
CAD and elevated serum triglyceride levels. In primate
evolution, emergence of such short indel variants and
indel-related transcriptional and translational changes
may have provided an additional source for the flexible
Figure 2 The human Na(+)-Ca(2+) exchanger (NCX1) gene: (a) Genomic structure shown in arbitrary scale (adapted from [8]; (b)
Hypervariable region within intron 2 (348 bp): identified human variants mapped on human-chimpanzee-macaque DNA sequence alignment.
The human polymorphisms (C = >G SNP, 43 bp deletion, 10 bp deletion, 40 bp duplication, 14 bp indel and 5 bp deletion) are highlighted by
arrows and in bold. Duplicons A and B of the 40 bp duplication are indicated in italics. Indel hotspot motifs GTAAG (reverse strand: CATTC;
[36,43] are underlined and enclosed in the brackets.
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environmental conditions. As a supportive observation,
an enrichment of indels in immunity-associated loci has
b e e nf o u n da sap o s s i b l er e s p o n s et ov a r i a b l ev i r u s
infections (i.e. HIV) in human and chimpanzee [32].
The human-specific deletion variant is surrounded by
an abundance of other short (5-43 bp) deletion variants
and a duplication (40 bp) polymorphism, which possess
overlapping breakpoints (Figure 2b). This observed high
variation refers to a potential indel hotspot, which may
have been triggered by the initial 14 bp deletion in
human lineage. This scenario is consistent with a recent
report revealing the mutag e n i cr o l eo ft h ei n d e l
heterozygosity to its surrounding sequences [33]. The
state of indel heterozygosity is expected to affect loca-
lized chromosome pairing during meiosis. Regions with
indel heterozygosity might be prone to double stranded
DNA breaks and are thus targeted to mutational repair,
which in turn leads to higher mutation rate [33,34]. A
consensus sequence motif GTAAG has been reported
with the high prevalence within genomic regions prone
to insertion/deletion events [35,36]. The sequence
(CATTCCCTCTCCAT) of the 14 bp indel identified in
this study contains the inverted sequence of this pre-
viously described hotspot motif on the reverse strand
(GTAAG vs. CATTC). In addition, the studied
Table 4 Association between cardiovascular disease and NCX1 intronic 14 bp indel rs11274804
Minor allele Association testing using logistic regression
1
frequency (%) Additive model Dominant model
Disease Sample Sample size
cases/
controls
2
Cases Controls P-value OR [95%CI] P-value OR [95%CI]
Essential hypertension HYPEST 470/652 7.76 9.04 0.14 0.70
[0.44, 1.12]
0.09 0.65
[0.40, 1.06]
Coronary artery disease CADCZ 257/413 12.45 7.02 0.0016 2.02
[1.30, 3.13]
0.0018 2.07
[1.31, 3.26]
Coronary artery disease & metabolic syndrome CADCZ 88/361 15.07 7.64 0.0014 2.34
[1.38, 3.96]
0.0016 2.41
[1.39, 4.18]
1Logistic regression analysis was performed with the following covariates: sex, age, BMI.
2Detailed definition of cases and controls for essential hypertension, coronary artery disease and metabolic syndrome is given in Materials and Methods, as well
as in additional file 2.
Significant differences have been highlighted in bold, P < 0.05.
Table 5 Association between cardiovascular parameters and the carrier status of the 14 bp indel in NCX1 intron 2
Association testing using linear regression
1
WT/WT WT/
indel
indel/
indel
Additive model Dominant model
Sample n Mean (± SD) Mean (± SD) Mean (± SD) P-value Effect (SE) P-value Effect (SE)
SBP (mmHg)
2 HYPEST 997 140.7 (21.19) 141.4 (22.93) 168.7 (36.14) 0.31 1.50 (1.47) 0.45 1.14 (1.52)
CADCZ 670 132.4 (20.29) 134.1 (22.00) 135.0 (18.03) 0.44 1.43 (1.85) 0.42 1.54 (1.92)
Meta-analysis 1667 137.4 (21.23) 138.4 (22.80) 151.8 (31.51) 0.20 1.47 (1.15) 0.28 1.29 (1.19)
Healthy subjects
3 1048 128.5 (5.66) 128.0 (10.53) 136.5 (9.19) 0.47 -0.71 (0.98) 0.39 -0.86 (0.99)
DBP (mmHg)
2 HYPEST 993 86.9 (12.67) 87.2 (13.31) 104.3 (22.28) 0.39 0.82 (0.95) 0.57 0.55 (0.98)
CADCZ 669 84.2 (11.51) 84.1 (15.45) 86.7 (11.55) 0.71 0.39 (1.07) 0.73 0.38 (1.11)
Meta-analysis 1662 85.8 (12.29) 85.9 (14.29) 95.5 (18.59) 0.38 0.63 (0.71) 0.51 0.48 (0.74)
Healthy subjects
3 1048 81.4 (1.41) 80.5 (7.85) 85.0 (7.07) 0.11 -1.06 (0.66) 0.08 -1.15 (0.67)
Heart rate (bpm) CADCZ 670 75.1 (5.51) 76.2 (5.83) 69.3 (3.06) 0.15 0.79 (0.54) 0.07 1.03 (0.56)
Healthy subjects
3 833 75.0 (8.49) 73.3 (8.06) 70.0 (0.00) 0.04 -1.61 (0.79) 0.05 -1.60 (0.80)
IMT
(mm)
CADCZ 670 0.63 (0.20) 0.65 (0.20) 0.87 (0.29) 0.20 0.03 (0.02) 0.33 0.02 (0.02)
CADCZ controls 413 0.58 (0.17) 0.54 (0.15) 1.20 (0.00) 0.42 -0.02 (0.02) 0.18 -0.03 (0.02)
1For association analysis with SBP and DBP regression testing for a linear trend of marker alleles was performed with age, sex and BMI as covariates. Association
analysis with heart rate was performed with sex as covariate, and intima-media thickness without covariates.
2Correction for antihypertensive treatment was implemented to all treated patients as described[25].
3Pooled HYPEST and CADCZ control subjects, who had no personal history of cardiovascular disease, including essential hypertension, myocardial infarction,
coronary artery disease, stroke, and had never been prescribed cardiovascular medications. Previously, no population differentiation was detected between
HYPEST and CADCZ study subjects[18]
n - number of individuals; IMT - Intima-media thickness; Significant differences have been highlighted in bold, p<0 . 0 5
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further CATTC motifs (Figure 2b). Low LD in this
region additionally refers to active genome dynamics
(See in additional file 3).
High prevalence of small indels (<100 bp) has been
found to be preferably associated with alternatively
spliced genes, where partial inclusion and deletion of
genic regions may broaden gene expression profiles in
different tissue types [32,36]. Among the 12 exons
coded by the human NCX1 gene there are six alternative
untranslated 5’-exons denoted 1a-1f. Different combina-
tions of these six exons may result in up to 32 different
Na
+/Ca
2+ exchanger mRNA transcripts [37]. The
hypothesis that preferences in splice-site selection
among NCX1 exons 1a-1f (and other alternative exons)
may be affected by the genetic composition in the
hypervariable intron 2 requires experimental proof.
The knowledge about the involvement of small indels
(<100 bp) in increasing/decreasing susceptibility to the
development of complex disease is still scarce. A well-
known example is 32 bp deletion in human the CCR5
gene that results in a frameshift and premature termina-
tion [38,39]. This variant, which is common among Eur-
opeans (MAF 9.2%) and almost absent among Africans
contributes to the resistance against HIV-1 infection. It
was speculated that a 10 bp direct repeat that flanks the
deleted region promoted a recombination event leading
to the 32 bp deletion [39]. The effect of indels in non-
coding regions is less understood. A recent study identi-
f i e da2 5b pd e l e t i o ni ni n t r o n3 2o ft h eh u m a n
MYBPC3 gene leading to the loss of exon 33. The car-
riers of this deletion develop heritable cardiomyopathies
and have increased risk of heart failure in Indian popu-
lations [40].
The current study identified a strong association
between the carrier status of NCX1 intronic 14 bp
indel and increased risk to coronary artery disease
(CAD) in the East European population. The risk was
the highest among the CAD patients with metabolic
disease. Consistent with the effect on metabolic pro-
cesses, the 14 bp indel was also associated with serum
triglyceride levels. Several recent studies have high-
lighted the role of metabolic factors and metabolic
syndrome in determining the extent of CAD and the
risk for new vascular events [41,42]. In perspective, the
association study of rs11274804 as well as other identi-
fied indel variants in NCX1 intron 2 with CAD and
related metabolic factors is to be extended to other
populations. The expression of NCX1 alternative tran-
scripts in vascular muscle (NCX1.3 isoform) and in
heart (NCX1.1 isoform) further supports the potential
involvement of NCX1 genetic variants in susceptibility
Table 6 Association between serum lipid biomarkers and the carrier status of the 14 bp indel in NCX1 intron 2
Association testing using linear regression
1
WT/WT WT/indel indel/
indel
Additive model Dominant model
Sample
2 n Mean (± SD) Mean (± SD) Mean (± SD) P-value Effect (SE) P-value Effect (SE)
Total cholesterol HYPEST 459 5.92 (1.15) 5.85 (1.24) 6.40 (2.47) 0.86 -0.02 (0.14) 0.73 -0.05 (0.15)
(mmol/L) CADCZ 670 5.50 (1.04) 5.48 (0.99) 5.55 (0.83) 0.11 0.17 (0.11) 0.14 0.17 (0.11)
Meta-analysis 1129 5.67 (1.10) 5.63 (1.10) 5.98 (1.71) 0.25 0.10 (0.09) 0.33 0.09 (0.09)
Healthy subjects
3 431 5.59 (1.07) 5.36 (0.98) 6.37 (0.00) 0.18 -0.19 (0.14) 0.14 -0.22 (0.15)
HDL (mmol/L) HYPEST 458 1.52 (0.42) 1.46 (0.42) 1.38 (0.29) 0.23 -0.06 (0.05) 0.24 -0.06 (0.05)
CADCZ 670 1.41 (0.39) 1.41 (0.42) 1.42 (0.29) 0.81 -0.009 (0.04) 0.82 -0.01 (0.04)
Meta-analysis 1128 1.45 (0.41) 1.43 (0.42) 1.40 (0.26) 0.35 -0.03 (0.03) 0.37 -0.03 (0.03)
Healthy subjects
3 431 1.52 (0.40) 1.61 (0.45) 1.70 (0.00) 0.10 0.09 (0.05) 0.10 0.09 (0.06)
LDL (mmol/L) HYPEST 459 4.04 (1.03) 4.04 (1.00) 4.66 (2.58) 0.73 0.04 (0.12) 0.88 0.02 (0.13)
CADCZ 651 3.33 (0.89) 3.22 (0.85) 3.22 (0.63) 0.66 -0.09 (0.20) 0.57 -0.12 (0.21)
Meta-analysis 1110 3.63 (1.01) 3.54 (1.00) 3.94 (1.85) 0.94 0.01 (0.11) 0.87 -0.02 (0.11)
Healthy subjects
3 427 3.41 (0.91) 3.13 (0.85) 3.94 (0.00) 0.06 -0.23 (0.12) 0.04 -0.26 (0.13)
Tri-glycerides HYPEST 458 1.77 (1.66) 1.82 (1.02) 1.29 (0.53) 0.99 0.003 (0.19) 0.89 0.03 (0.20)
(mmol/L) CADCZ 670 1.72 (1.19) 1.94 (1.27) 2.00 (1.16) 0.04 0.25 (0.12) 0.04 0.26 (0.12)
Meta-analysis 1128 1.74 (1.40) 1.89 (1.18) 1.65 (0.90) 0.08 0.18 (0.10) 0.07 0.19 (0.10)
Healthy subjects
3 431 1.52 (1.12) 1.40 (0.81) 1.62 (0.00) 0.44 -0.11 (0.15) 0.42 -0.12 (0.15)
1For association analysis with serum lipids regression testing for a linear trend of marker alleles was performed with age, sex and BMI as covariates.
2Correction for the treatment with lipid-lowering medication was implemented as described[24].
3Pooled HYPEST and CADCZ control subjects with available records for serum lipids. The individuals had no personal history of cardiovascular disease, including
essential hypertension, myocardial infarction, coronary artery disease, stroke, and had never been prescribed cardiovascular medications. Previously, no
population differentiation was detected between HYPEST and CADCZ study subjects[18]
n - number of individuals; Significant differences have been highlighted in bold, p<0 . 0 5
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Page 10 of 12to coronary artery disease [7]. Functional studies would
reveal whether the carrier status of alternative NCX1
intronic indel variants affects the alternative transcript
profile of the gene.
Conclusions
In summary, compared to SNPs targeted by large
number of locus-specific and genome-wide assays, con-
siderably less attention has been paid to short inser-
tion-deletions (indels) variants in the human genome.
The data of genome dynamics, mutation rate and
population genetics of short indels, as well as their
impact on gene expressional profile and human disease
susceptibility is limited. The characterization of NCX1
intronic hypervariable region enriched in human-speci-
fic indel variants contributes to this gap of knowledge.
Additional file 1: Characteristics of analyzed DHPLC and DGGE
regions. All analyzed NCX1 gene regions for DHPLC and DGGE assays.
Characteristics of 29 regions: their location, conservation, PCR primers
and product length, found polymorphisms and the reason for exclusion
form the study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2350-11-
15-S1.XLS]
Additional file 2: Additional information for Materials and Methods.
Additional information for Materials and Methods.
Click here for file
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Additional file 3: LD structure of the human NCX1 gene 348 bp
region. LD structure of the human NCX1 gene region (chr2; position: 40
241 046-40 661 226) shown as r
2-blot. Upper white bar marks the
positions of HapMap SNPs. Both arrows indicate the location of 14 bp
indel (rs11274804) between two LD-blocks in the second intron of the
NCX1 gene.
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